Biopharma cold-chain market forecast

The 9th edition of Pharmaceutical Commerce’s Biopharma Cold Chain Sourcebook details a trend that has continued almost since the first edition in 2008: biologics are entering the market at substantially higher rate than small-molecule drugs; combined with the growth of […]

Read More

Pharma traceability lumbers along

The modernization of the US drug supply chain is now halfway through the timeline set by the Drug Supply Chain Security Act (DSCSA): it’s been five years since the law was passed, and in five years (if all goes according […]

Read More

The Hub Services Wheel keeps Rolling Along

The year 2017 was another one with more launches of specialty pharmaceuticals than conventional mass-market ones, continuing the shift of the branded pharma industry into the branded specialty pharma one. This shift has been generating more and more business for […]

Read More

2017 Hub Services report

Nature, as we’re told, abhors a vacuum. In the past, as new specialty pharmaceutical products came onto the market, a vacuum of sorts developed as healthcare providers (HCPs), pharmacists and the drugmakers themselves realized that the new drugs needed additional […]

Read More
| 2 Comments